Nicoya Revenue and Competitors
Estimated Revenue & Valuation
- Nicoya's estimated annual revenue is currently $18.9M per year.
- Nicoya's estimated revenue per employee is $191,010
- Nicoya's total funding is $28.2M.
Employee Data
- Nicoya has 99 Employees.
- Nicoya grew their employee count by -6% last year.
Nicoya Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $3.7M | 29 | -34% | $39.4M | N/A |
#2 | $5.5M | 56 | 2% | $23.8M | N/A |
#3 | $79.8M | 515 | 19% | N/A | N/A |
#4 | $3.7M | 16 | -20% | N/A | N/A |
#5 | $6.4M | 41 | -68% | N/A | N/A |
#6 | $17.4M | 90 | 15% | N/A | N/A |
#7 | $14.9M | 84 | 18% | $86M | N/A |
#8 | $27.4M | 177 | -31% | N/A | N/A |
#9 | $2M | 13 | 8% | N/A | N/A |
#10 | $3.3M | 21 | 62% | N/A | N/A |
What Is Nicoya?
Nicoya Lifesciences is a nanotechnology company developing sensor products that will change the world of biotechnology, lifesciences, and healthcare. Our technology is based on the unique optical properties of nanomaterials, also called nanophotonics. Using revolutionary nanosensing technology, we can detect a wide range of biomolecules at extremely small concentrations in a compact, low cost, rapid, and easy to use format. Our first product is OpenSPR, which is a powerful and affordable instrument for label-free interaction analysis. Interactions between proteins, antibodies, DNA, RNA, peptides, polymers, and more can be studied with nanoscale resolution. This is critical for research and development applications in many fields from pharmaceuticals to diagnostics. OpenSPR is compact, portable, easy to use, and best of all, priced so everyone can afford it.
keywords:N/A
$28.2M
Total Funding
99
Number of Employees
$18.9M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nicoya News
Amidst the tropical greens of the Nicoya Peninsula of Costa Rica grows the chan plant, which produces this lesser-known seed.
Pura Vida: Nina Parker's guide to Costa Rica's Nicoya Peninsula. After spending a fortnight travelling around this famed Blue Zone,...
The round, led by food innovation-focused venture capital fund Nicoya AB (publ) of Stockholm, Sweden, and Raiven Capital of Toronto, Canada,...
Kitchener-Waterloo-based healthtech startup Nicoya has announced it is set to receive more financial support and advisory services from the Government of Canada to continue the research and development of its rapid, saliva-based COVID-19 antigen test, Atlas. Arjun Sudarsan, Nicoya’s CTO, claims ...
KITCHENER, Ontario, April 6, 2021 /PRNewswire/ -- Nicoya Lifesciences, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, is pleased to announce that it is receiving additional advisory services and funding to continue research and develo ...
Other Companies in Kitchener
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21.8M | 99 | 5% | N/A |
#2 | $15.5M | 107 | 6% | $11M |
#3 | $33.2M | 109 | 10% | N/A |
#4 | $31.9M | 110 | 4% | N/A |
#5 | $15M | 113 | 0% | N/A |
Nicoya Executives
| Name | Title |
|---|---|
| Arjun Sudarsan | CTO |
| Ryan Denomme | Founder and CEO |
| Colin Calvert | Chief Financial Officer |
| Patrick Sterlina | Chief of Engineering |
| Brian Ward | VP Operations |
